NEW YORK, July 11, 2026 – The biotech sector faced a significant downturn this week, with major players Vertex Pharmaceuticals (NASDAQ:VRTX) and Ionis Pharmaceuticals (NASDAQ:IONS) suffering substantial losses. A pair of disappointing developments erased approximately $14.8 billion in market value over the five trading sessions ending Friday, based on share counts from July 2 and closing prices on July 10.
Vertex's B Deal and Crinetics Surge
Vertex announced a $10 billion acquisition of Crinetics Pharmaceuticals (NASDAQ:CRNX), offering $85 per share—a 102% premium over Monday's close. This deal propelled Crinetics shares up nearly 98% for the week, adding about $4.3 billion in value. The acquisition brings Vertex two key assets: Palsonify, an approved treatment for acromegaly, and atumelnant, a late-stage candidate. The companies project combined peak annual sales exceeding $5 billion. Scotiabank analyst Louise Chen noted this expands Vertex into endocrinology as a fifth business line. CEO Reshma Kewalramani affirmed that Vertex's capital allocation strategy remains unchanged.
Despite the acquisition news, Vertex shares dropped 8.1% for the week, losing roughly $10.9 billion in market cap, as investors weighed integration risks and the premium paid.
Ionis and Wainua Trial Failure
Ionis Pharmaceuticals faced a sharp 28.8% decline after its drug Wainua, developed in partnership with AstraZeneca (NASDAQ:AZN), failed to meet its primary endpoint in a Phase 3 trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The drug did not significantly reduce cardiovascular deaths and recurrent cardiac events, dashing expectations for potential peak sales of $2 billion. BofA analyst Sachin Jain described the data as a surprise. The trial design revealed that 57% of patients were already on a transthyretin stabilizer at baseline, and another 24% initiated one during the study. Wainua showed no benefit in the stabilizer group but a suggestive, non-conclusive effect when used alone. This divergence helped BridgeBio (NASDAQ:BBIO), which manufactures the stabilizer Attruby, gain 11.3% for the week. Alnylam Pharmaceuticals (NASDAQ:ALNY), developer of the gene-silencer Amvuttra, saw shares pop 17% intraday on Thursday but closed the week down 4.5%.
Vera Therapeutics Gains FDA Approval
Vera Therapeutics (NASDAQ:VERA) received accelerated FDA approval for Trutakna, a treatment for IgA nephropathy, a kidney disease caused by immune deposits. The approval was based on early markers—specifically a 42% reduction in urine protein at 36 weeks compared to placebo. Chief Commercial Officer Matt Skelton set the wholesale price at $425,000 per year. Shares ended the week up just 1.9%, adding about $100 million in market value.
Biotech Sector and Market Context
The SPDR S&P Biotech ETF (NYSEARCA:XBI) fell 0.9% for the week, while the broader SPDR S&P 500 ETF (NYSEARCA:SPY) rose 1.4%. Money rotated within biotech, with approved drugs, M&A activity, and trial outcomes driving sharp divergences. The sector continues to see a split between winners and losers, as weak evidence is heavily penalized.
Apnimed Files for IPO
Apnimed filed for an initial public offering on Friday, planning to list on the Nasdaq under the ticker APMD. This comes amid a slump in biotech IPOs, which hit their lowest level in over a decade in 2025. The filing suggests the IPO window may be slowly reopening. Apnimed's lead drug, AD109, has a marketing application pending, with an FDA decision expected in the first quarter of 2027.
Key Catalysts Ahead
Investors will watch two major events next week. On Monday, July 13, Q32 Bio (NASDAQ:QTTB) releases 36-week data for bempikibart in alopecia areata at 8:00 a.m. EDT, testing clinical durability. On Friday, July 17, the FDA is set to rule on Celcuity's (NASDAQ:CELC) gedatolisib for a type of advanced breast cancer, with priority review potentially leading to approval and launch.
This week's moves underscore that biotech demand remains, but the broad rebound has given way to stock-picking. Weak trial results are being punished fully, while M&A and approvals reward select names.
